ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

Mysterious Group Urges Letters In Support Of Fisher, Calls For Investigation of NCI

April 22, 1994

Congress Cuts $210 Million From NIH Budget For The Remainder of 2011

April 15, 2011

Weicker Negotiating For 6,000 NIH Grants In Both 1985, 1986; Societies Appeal For Adequate Funding

May 10, 1985

Coalitions Urges Members To Call, Write, Congress

May 3, 1991

Cancer Control Contract Negotiations To Start Soon; Two Weaknesses Occur In Many Proposals

March 7, 1975